Commodore Capital
Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Commodore Capital Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
9,173,899Website Global Rank
195Website Monthly Traffic
Twitter Followers
Description
Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 5/2022 | Celcuity | Post-IPO Equity | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 7/2022 | Arkive | Seed Round | 0 |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 7/2021 | Nimbus Therapeutics | Private Equity Round | 105M |
| 2/2021 | Shoreline Biosciences | Series A | 0 |
| 10/2022 | Immunovant | Post-IPO Equity | 75M |
| 7/2022 | Arkive | Seed Round | 0 |
| 5/2022 | Celcuity | Post-IPO Equity | 0 |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 7/2021 | Nimbus Therapeutics | Venture Round | 0 |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2021 | Shoreline Biosciences | Series A | 0 |
| 8/2020 | Kronos Bio | Private Equity Round | 0 |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 0 |
| 6/2020 | C4 Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
